• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA issues warning letter to Sanofi-aventis

FDA issues warning letter to Sanofi-aventis

March 1, 2011
CenterWatch Staff

The FDA has warned Sanofi-Aventis’ U.S. unit for failing to submit reports of possible serious drug side effects in a timely manner. In a Jan. 28 letter made public last week, the FDA said an early response from the drugmaker and its "promised corrective actions are inadequate to address the deficiencies."

Sanofi spokesman Jack Cox said the company acknowledged the FDA's observations and is working with it to comply. The letter stems from agency inspections of Sanofi's Bridgewater, N.J., facility in April and May 2010, where it found Sanofi had inadequate procedures in place to monitor adverse events and failed to submit serious and unexpected adverse drug experiences by the FDA's deadline.

It also did not include information on postmarketing studies for several drugs—including diabetes drug Apidra, colon cancer drug Eloxatin and antibiotic Ketek—in its annual report to the FDA. Information on completed, unpublished clinical trials of Apidra, Eloxatin and sleep aid Ambien were also not submitted as required.

Sanofi responded to the agency in June, July and October 2010 with plans to correct the problem, but the FDA said its response was lacking. It told Sanofi to take prompt action and respond within 15 days.

Separately, the FDA warned Sanofi's German unit regarding manufacturing violations that led to contamination issues. That letter, dated Feb. 9, cited Sanofi for not having proper written or manufacturing procedures in place or staff properly trained to prevent contamination. Sanofi's Cox said it had moved quickly to address the problems and takes the matter seriously.

 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing